A Case of Acquired Generalized Lipodystrophy Associated with Pembrolizumab in a Patient with Metastatic Malignant Melanoma
Bedrose S, Turin C, Lavis V, Kim S, Thosani S. A Case of Acquired Generalized Lipodystrophy Associated with Pembrolizumab in a Patient with Metastatic Malignant Melanoma. AACE Clinical Case Reports 2020, 6: e40-e45. PMID: 32524008, PMCID: PMC7279776, DOI: 10.4158/accr-2019-0234.Peer-Reviewed Original ResearchImmune-related adverse eventsAcquired generalized lipodystrophyPatients treated with pembrolizumabLoss of subcutaneous fatImmune-checkpoint inhibitorsInitiation of pembrolizumabTreated with pembrolizumabCheckpoint inhibitor therapyMetastatic malignant melanomaAutoimmune hemolytic anemiaUnexplained weight lossWorsening insulin resistanceWorsening hypertriglyceridemiaCheckpoint inhibitorsMetastatic melanomaInhibitor therapyTreat several typesGeneralized lipodystrophyPembrolizumabIrreversible complicationsMalignant melanomaAutoimmune disordersCase reportAdverse eventsHemolytic anemia